Join the Oncology Voice Network. Join for Free
The DARK Side of MSL-ing-What No One Tells YOU
Medical Science Liaison Key Opinion Leaders career journey challenges faced successful networking

The DARK Side of MSL-ing-What No One Tells YOU


Share This Article


Summary

In this episode, Kirsten Gurtowsky shares her experiences and insights as a Medical Science Liaison. She discusses her career journey, highlighting the balance and flexibility required in the MSL role, as well as the challenges faced. Kirsten delves into the importance of building strong relationships with Key Opinion Leaders and offers strategies for successful networking and engagement. She also provides guidance for aspiring MSLs, drawing on her professional experiences. The episode concludes with Kirsten sharing her excitement and goals for the upcoming year, followed by expressions of appreciation.

Kirsten Gurtowsky, Medical Science Liaison with Novartis, discusses the dark side of being an MSL and what you may not be aware of

Kirsten shares….

👉 What she LOVES about being an MSL
👉 What some of the main frustrations are for MSLs
👉 The challenges of travel and uncertainty
👉 The frustrations that come with paperwork and metrics
👉 Her insights and predictions for 2024

Click for Source
Medical Science Liaison, Key Opinion Leaders, career journey, challenges faced, successful networking

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
Social Media Listening Evolved
Partner Avatar MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson

Social Media Listening Evolved

Podcast
Over-Negotiation-How to Botch a Job Offer
Partner Avatar MSL Talk: Tom Caravela

Over-Negotiation-How to Botch a Job Offer

Article
Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology
OVN Avatar Sonoko Kawakatsu, René Bruno, Matts Kågedal, Chunze Li, Sandhya Girish, Amita Joshi, Benjamin Wu

Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology

Article
Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals
OVN Avatar R. Kurzrock, L.A. Gurski, R.W. Carlson, D.S. Ettinger, S.M. Horwitz, S.K. Kumar, L. Million, M. von Mehren, A.B. Benson III

Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals

Article
EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies
OVN Avatar Barbara Kiesewetter , Nathan I Cherny, Nicolas Boissel, Francesco Cerisoli, Urania Dafni, Elisabeth G E de Vries, Paolo Ghia, Nicola Gökbuget, Verónica González-Calle, Brian Huntly, Ulrich Jäger, Nicola Jane Latino, Jean-Yves Douillard, Luca Malcovati, Ma

EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies

Article
The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions
OVN Avatar Charles L. Bennett , Sumimasa Nagai , Andrew C. Bennett , Shamia Hoque , Chadi Nabhan , Martin W. Schoen , William J. Hrushesky , Stefano Luminari , Paul Ray , Paul R. Yarnold , Bart Witherspoon , Josh Riente , Laura Bobolts , John Brusk , Rebecca Tombles

The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions

Explore OVN